文献速递肝病消化道肿瘤与早癌

肝硬化乙型肝炎患者有限疗程治疗后肝细胞癌减少、HBsAg清除增加且生存改善

Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
PubMed 文献 · Hepatology · 2023-08-25

该研究纳入2个中心的494例停用核苷(酸)类似物(Nuc)治疗的HBeAg阴性HBV相关肝硬化患者与593例继续治疗者,按1:1倾向性评分匹配后比较。中位随访6.2年,有限疗程组的肝癌年发病率和10年发病率均低于持续治疗组,HBsAg清除率更高,肝癌、肝病相关死亡/移植及总体死亡风险更低。

要点

  • 有限疗程组肝癌年发病率为1.6%/年,持续治疗组为3.3%/年,10年累计发病率分别为15.7%与26.8%(p<0.0001)。
  • 有限疗程组10年HBsAg清除率为22.7%,持续治疗组为3%,前者约为后者的7.6倍(p<0.0001)。
  • 多因素Cox回归显示有限疗程是HBsAg清除的独立因素(校正HR 11.79),并对肝癌(校正HR 0.593)、肝病相关死亡/移植(校正HR 0.312)和总体死亡(校正HR 0.382)具保护作用。

核心结论

  • 在HBeAg阴性HBV相关肝硬化患者中,有限疗程Nuc治疗可能降低肝癌发病率、提高HBsAg清除率并改善生存。
  • HBsAg下降幅度更大及HBsAg清除可能反映免疫力增强,并有助于减少肝癌发生。

研究设计与样本

  • 多中心(2个中心)队列研究,纳入494例停用Nuc治疗的HBeAg阴性HBV相关肝硬化患者(有限疗程组)和593例继续治疗者(持续治疗组)。
  • 按性别、治疗史、Nuc种类、年龄、转氨酶、血小板计数及有限疗程组治疗结束时或持续治疗组治疗3年时的HBsAg水平进行1:1倾向性评分匹配。
  • 中位随访6.2(3.4-8.9)年。

主要发现

  • 肝癌年发病率有限疗程组1.6%/年 vs 持续治疗组3.3%/年,10年累计发病率15.7% vs 26.8%(log-rank检验,p<0.0001)。
  • HBsAg年下降幅度有限疗程组-0.116 log10 IU/mL vs 持续治疗组-0.095 log10 IU/mL(p=0.0026)。
  • 10年HBsAg清除率有限疗程组22.7% vs 持续治疗组3%,前者为后者的7.6倍(p<0.0001)。
  • 多因素Cox回归:有限疗程为HBsAg清除的独立因素(校正HR 11.79),对肝癌(校正HR 0.593)、肝病相关死亡/移植(校正HR 0.312)和总体死亡(校正HR 0.382)具保护作用。

临床怎么用

  • 作者认为,在HBeAg阴性HBV相关肝硬化患者中,有限疗程Nuc治疗可能降低肝癌发病率、提高HBsAg清除率并改善生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Long-term nucleos(t)ide analog (Nuc) treatment can reduce HCC in patients with HBV-related liver cirrhosis (HBV-LC). Earlier small cohort studies showed a comparable 5-year incidence of HCC in HBeAg-negative patients with HBV-LC who stopped and those continued Nuc therapy. This study aimed to validate these findings using a large cohort with 10-year follow-up. APPROACH AND RESULTS: From 2 centers, 494 HBeAg-negative patients with HBV-LC who stopped (finite group) and 593 who continued (continuous group) Nuc therapy were recruited. HCC, HBsAg loss, liver-related mortality/transplantation, and overall survival rates were compared between 2 groups with 1:1 propensity score matching of sex, treatment history, types of Nuc, age, transaminases, platelet count, and HBsAg levels at end of therapy in finite group or 3-year on-therapy in continuous groups. During a median follow-up of 6.2 (3.4-8.9) years, the annual and 10-year HCC incidence were lower in finite group (1.6 vs. 3.3%/y and 10-y 15.7% vs. 26.8%, respectively; log-rank test, p <0.0001). The finite group showed greater HBsAg decline/year (-0.116 vs. -0.095 log 10 IU/mL, p =0.0026) and 7.6 times higher 10-year incidence of HBsAg loss (22.7% vs. 3%, p <0.0001). Multivariate Cox regression showed finite therapy an independent factor for HBsAg loss (adjusted HR: 11.79) but protective against HCC (adjusted HR: 0.593), liver-related mortality/transplantation (adjusted HR: 0.312), and overall mortality (adjusted HR: 0.382). CONCLUSIONS: Finite Nuc therapy in HBeAg-negative HBV-LC may reduce HCC incidence, increase HBsAg loss, and improve survival. Greater HBsAg decline/loss may reflect enhanced immunity and contribute to the reduction of hepatic carcinogenesis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jeng WJ, Chien RN, Chen YC, et al. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis. Hepatology. 2023. PMID: 37625144. doi:10.1097/HEP.0000000000000575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。